share_log

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

传奇生物 | 6-K:传奇生物宣布CARVYKTI获欧盟委员会批准用于复发难治性多发性骨髓瘤患者的二线治疗
美股sec公告 ·  04/22 13:11
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息